脓毒症免疫代谢:从定义脓毒症到理解能量产生如何影响免疫反应
本文为综述,检视脓毒症当前定义与管理趋势,以及动物和离体研究中能量产生下降与脓毒症过程中炎症反应紊乱相关的病理生理机制。脓毒症是感染所致死亡的主要原因,也是美国治疗费用最高的疾病之一;尽管有精准定义脓毒症的努力、新型治疗和高训练有素的提供者,脓毒症死亡率仍居高不下。过去数十年脓毒症定义因标准界定不清及严重脓毒症与脓毒性休克管理指南不明确而不断变迁。早期识别将从全身炎症反应进展为脓毒性休克的患者至关重要,因为近期传统治疗如早期目标导向治疗、静脉免疫球蛋白和抗肿瘤坏死因子-α抗体均已失败。由于复杂的炎症与代谢交互作用,目前尚无有效的抗脓毒症药物治疗。
要点
- 脓毒症是感染所致死亡的主要原因,也是美国治疗费用最高的疾病之一,尽管治疗进步死亡率仍高。
- 早期识别将从全身炎症反应进展为脓毒性休克的患者至关重要。
- 近期传统治疗如早期目标导向治疗、静脉免疫球蛋白和抗肿瘤坏死因子-α抗体均已失败。
- 动物和离体研究显示能量产生下降与脓毒症过程中炎症反应紊乱相关。
- 由于复杂的炎症与代谢交互作用,目前尚无有效的抗脓毒症药物治疗。
红旗征与不能漏的情况
- 全身炎症反应患者有进展为脓毒性休克的风险,早期识别此类患者至关重要。
研究设计与关键结果
- 综述检视脓毒症当前定义与管理趋势,以及动物和离体研究中能量产生下降与脓毒症过程中炎症反应紊乱相关的病理生理机制。
- 脓毒症定义在过去数十年因标准界定不清及严重脓毒症与脓毒性休克管理指南不明确而不断变迁。
- 近期传统治疗如早期目标导向治疗、静脉免疫球蛋白和抗肿瘤坏死因子-α抗体均已失败。
- 由于复杂的炎症与代谢交互作用,目前尚无有效的抗脓毒症药物治疗。
证据类型、等级与局限
- 证据类型:综述,纳入文献中最相关的原创文章。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需进一步研究先天免疫与代谢之间的交互界面,以有效应对脓毒症患者死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This review will examine current definitions and trends in sepsis management as well pathophysiologic mechanisms in animal and ex vivo studies that correlate decreased energy production with deranged inflammatory response during the septic process.
DATA SOURCES: The latest articles in the literature that focus on the role of immunometabolism and associated mechanisms in sepsis were selected.
STUDY SELECTION: The most relevant, original articles were included in the review.
DATA EXTRACTION: All pertinent data for sepsis definitions as well as changes in immunometabolic pathways during the septic process was reviewed and assessed for inclusion in this article.
DATA SYNTHESIS: Sepsis is a major cause of multiple organ dysfunction. It is the principal cause of death resulting from infection and one of the most expensive conditions treated in the United States. Despite current efforts to accurately define sepsis, novel treatments and highly trained providers, mortality rates for sepsis remain high, prompting a need for further investigation of underlying immunometabolic mechanisms to identify potential treatment targets. The definition of sepsis has shifted and changed in the past few decades due to poorly defined criteria, as well as unclear guidelines for providers with regards to management of severe sepsis and septic shock. The early identification of patients with a systemic inflammatory response that will progress to septic shock is critical since recent traditional therapeutic approaches, such as early goal-directed therapy, IV immunoglobulin, and anti-tumor necrosis factor-α antibodies have failed.
CONCLUSIONS: There are no effective anti-sepsis drug therapies due to complex inflammatory and metabolic interactions. Further studies regarding the interface between innate immunity and metabolism should be investigated to effectively address septic patient mortality rates.
参考来源
- Koutroulis I, Batabyal R, McNamara B, et al. Sepsis Immunometabolism: From Defining Sepsis to Understanding How Energy Production Affects Immune Response. Crit Care Explor. 2019. PMID: 32166242. doi:10.1097/CCE.0000000000000061
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。